Integrating structure-based and ligand-based approaches for computational drug design

scientific article

Integrating structure-based and ligand-based approaches for computational drug design is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.4155/FMC.11.18
P698PubMed publication ID21554079

P2093author name stringMarkus A Lill
Gregory L Wilson
P2860cites workChemical Similarity SearchingQ28090770
P433issue6
P304page(s)735-750
P577publication date2011-04-01
P1433published inFuture Medicinal ChemistryQ19280078
P1476titleIntegrating structure-based and ligand-based approaches for computational drug design
P478volume3

Reverse relations

cites work (P2860)
Q92589923A Structure-Based Drug Discovery Paradigm
Q49226937A perspective on multi-target drug discovery and design for complex diseases.
Q38750215Active learning for computational chemogenomics
Q35206344Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design.
Q51709866Computational medicinal chemistry: part II.
Q26997089Computational methods in drug discovery
Q47319211Computational modeling in glioblastoma: from the prediction of blood-brain barrier permeability to the simulation of tumor behavior.
Q36758674Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential
Q91666838Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches
Q26745421Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies
Q50940415Enhancing the Reliability of GPCR Models by Accounting for Flexibility of Their Pro-Containing Helices: the Case of the Human mAChR1 Receptor.
Q35158672Focused chemical libraries--design and enrichment: an example of protein-protein interaction chemical space
Q26824875Global phenotypic screening for antimalarials
Q36912176Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening
Q89597711In Silico Strategies in Tuberculosis Drug Discovery
Q99545642In silico design and molecular docking study of CDK2 inhibitors with potent cytotoxic activity against HCT116 colorectal cancer cell line
Q93126855Molecular Docking: Shifting Paradigms in Drug Discovery
Q26800097Molecular docking and structure-based drug design strategies
Q41478711Novel selective, potent naphthyl TRPM8 antagonists identified through a combined ligand- and structure-based virtual screening approach
Q51527954Pharmacophore modeling, 3D-QSAR, and in silico ADME prediction of N-pyridyl and pyrimidine benzamides as potent antiepileptic agents.
Q50252143Probing voltage sensing domain of KCNQ2 channel as a potential target to combat epilepsy: a comparative study.
Q93202753Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process
Q38252759Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
Q38553677Role of computer-aided drug design in modern drug discovery.
Q64273189Structural Perspective on Revealing and Altering Molecular Functions of Genetic Variants Linked with Diseases
Q39003333Target-based molecular modeling strategies for schistosomiasis drug discovery.
Q51603763Towards a Realistic Representation in Surface-Based Pseudoreceptor Modeling: a PDB-Wide Analysis of Binding Pockets.
Q48184670Toxicodynamics of Mycotoxins in the Framework of Food Risk Assessment-An In Silico Perspective
Q38933291Use of Integrated Computational Approaches in the Search for New Therapeutic Agents

Search more.